Log in
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 

MarketScreener Homepage  >  Equities  >  Bolsas y Mercados Espanoles  >  Almirall, S.A.    ALM   ES0157097017


SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector newsAnalyst Recommendations

Almirall S A : The Board of Directors nominates Carlos Gallardo as Vice President of the Board

11/09/2020 | 02:28am EST
The Board of Directors nominates Carlos Gallardo as Vice President of the Board 09 November 2020
  • Third generation of the family to take on a more significant role within the Board of Directors
  • Nomination of Carlos Gallardo demonstrates commitment of the family to Almirall's future

Almirall, S.A. (ALM) the global biopharmaceutical company based in Barcelona, has announced the nomination of Carlos Gallardo as Vice President of the Board of Directors effective immediately.

This is an important step in a very well thought out plan that was initiated over two years ago and after evaluating several candidates for the position. The Board of Directors has taken this measure following a rigorous process where Carlos has taken on increasing levels of responsibility within the Board of Directors as part of a broader development plan. Moreover, Carlos has been increasingly involved in several key committees within Almirall, including the Pipeline Committee and the Digital Steering Committee, which he chairs. This deep immersion has prepared him for his new expanded responsibilities.

Jorge Gallardo Ballart, Chairman of the Board of Directors, commented, 'Carlos represents the third generation of the Gallardo Family to lead and grow the company. We are pleased that he is taking this important step to take on more significant responsibilities within the Board and represents the Gallardo Family's continued support and commitment to Almirall. This appointment recognizes his increasing contributions to the company and acknowledges the value that his involvement has garnered.'

Carlos has broad international healthcare experience. He started his pharmaceutical career in Pfizer prior to joining Almirall where he held positions of increasing seniority over nearly 10 years. Since leaving Almirall as General Manager of the UK and Ireland in 2013, Carlos has served as a member of Almirall's Board of Directors. In addition, he has established a successful career as a venture capitalist investing in digital health. He is the founder and CEO of CG Health Ventures where he invests in and builds digital health companies that match technology and talent to solve for challenges in healthcare. He serves on a number of boards of promising early stage digital health and health technology startups. Carlos holds an MS in industrial Engineering from the Universitat Politècnica de Catalunya and an MBA from Stanford University's Graduate School of Business.

According to Carlos, 'I am very pleased to assume this new role and to continue to help bring the company to the next level. Almirall is poised for growth and it is exciting to be more involved in that trajectory. I am looking forward to combining my expertise as a venture capital investor and in pharma to continue to bring innovation to the company and future proof our efforts going forward.'

About Almirall

Almirall is a global biopharmaceutical company focused on skin health. We collaborate with scientists and healthcare professionals to address patient's needs through science to improve their lives. Our Noble Purpose is at the core of our work: 'Transform the patients' world by helping them realize their hopes and dreams for a healthy life'. We invest in differentiated and ground-breaking medical dermatology products to bring our innovative solutions to patients in need.

The company, founded in 1943 and headquartered in Barcelona, is publically traded on the Spanish Stock Exchange and is a member of the IBEX35 (ticker: ALM). Throughout its 77-year history, Almirall has retained a strong focus on the needs of patients. Currently, Almirall has a direct presence in 21 countries and strategic agreements in over 70, through 13 subsidiaries, with about 1,800 employees. Total revenues in 2019 were 908.4 million euros.

For more information, please visit almirall.com


Almirall SA published this content on 09 November 2020 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 09 November 2020 07:27:02 UTC

© Publicnow 2020
All news about ALMIRALL, S.A.
2020Athenex Secures FDA Approval for Klisyri in Treating Actinic Keratosis
2020ALMIRALL S A : announces FDA approval of Klisyri® (tirbanibulin), a new innovati..
2020ALMIRALL S A : has selected six digital health start-ups to join the second harv..
2020ALMIRALL S A : Pablo Alvarez appointed to President and GM of Almirall US
2020ALMIRALL S A : demonstrates resilient performance year to date despite COVID-19 ..
2020ALMIRALL S A : The Board of Directors nominates Carlos Gallardo as Vice Presiden..
2020ALMIRALL, S.A. : 3rd quarter results
2020ALMIRALL S A : First complete dataset in the IL-23p19 class demonstrates ILUMETR..
2020ALMIRALL S A : announces approval of the reimbursed price for Ilumetri®(tildraki..
2020ALMIRALL S A : announces approval of the reimbursed pricefor Ilumetri®(tildrakiz..
More news
Sales 2020 831 M 1 003 M 1 003 M
Net income 2020 87,2 M 105 M 105 M
Net Debt 2020 374 M 452 M 452 M
P/E ratio 2020 23,3x
Yield 2020 1,66%
Capitalization 2 071 M 2 505 M 2 502 M
EV / Sales 2020 2,94x
EV / Sales 2021 2,58x
Nbr of Employees 1 820
Free-Float 40,3%
Duration : Period :
Almirall, S.A. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ALMIRALL, S.A.
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus BUY
Number of Analysts 9
Average target price 15,24 €
Last Close Price 11,63 €
Spread / Highest target 59,1%
Spread / Average Target 31,0%
Spread / Lowest Target -14,0%
EPS Revisions
Managers and Directors
Jorge Gallardo Ballart Chairman
Eloi Crespo Cervera Senior Vice President-Industrial Operations
Michael McClellan Chief Financial Officer
Bhushan D. Hardas Chief Scientific Officer
Volker Koscielny Chief Medical Officer
Sector and Competitors
1st jan.Capitalization (M$)
ALMIRALL, S.A.6.50%2 505
JOHNSON & JOHNSON1.86%421 997
ROCHE HOLDING AG2.48%305 385
NOVARTIS AG1.97%218 041
MERCK & CO., INC.1.93%210 954
PFIZER INC.-0.30%203 993